Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BTOG 2023 | Evolving treatment landscape of mesothelioma

Kevin Blyth, MBChB, MD, FRCP, University of Glasgow, Glasgow, UK, reflects on the evolving treatment landscape of mesothelioma, highlighting combination immunotherapy as the new standard of care for this patient population. Dr Blyth also touches on current unmet needs such as therapeutic approaches for patients who do not respond to checkpoint inhibition, as well as optimal management of early-stage mesothelioma which is becoming of increased importance due to improvements in the diagnostic pathway. This interview took place at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 in Belfast, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Research funding from Rocket Medical and Asbestos Action. Received fees for advisory boards from Rocket Medical, Lily and BMS. Trustee of Mesothelioma UK.